Gilead CFO exercises 2,797 RSUs, 1,347 withheld

Gilead Sciences’ CFO exercised 2,797 RSUs, with 1,347 shares withheld to cover the exercise price or tax obligations.

Rhea-AI Filing Summary

GILEAD SCIENCES, INC. (GILD) reported that Chief Financial Officer Andrew D. Dickinson exercised restricted stock units for 2,797 shares of common stock on September 10, 2026. The same number of RSUs was converted and removed, and 1,347 shares of common stock were delivered or withheld to cover the exercise price or tax liability, leaving 25,054 restricted stock units directly held. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

2,797 shares exercised/converted

Exercise 3 txns

Insider Dickinson Andrew D

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F1, F2	2,797	--	--
Exercise	Common Stock F1	2,797	--	--
Exercise Price or Tax Liability	Common Stock	1,347	$144.81	$195K

Holdings After Transaction: Restricted Stock Unit — 25,054 contracts (Direct); Common Stock — 167,096 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
2. F2. The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

Key Figures

RSUs exercised: 2,797 units Common shares acquired from RSU exercise: 2,797 shares Shares delivered or withheld for exercise price or tax liability: 1,347 shares +4 more

7 metrics

RSUs exercised 2,797 units Restricted stock units converted into common stock on September 10, 2026

Common shares acquired from RSU exercise 2,797 shares Common stock received upon RSU conversion on September 10, 2026

Shares delivered or withheld for exercise price or tax liability 1,347 shares Code F transaction on September 10, 2026

Per-share value for tax/exercise settlement $144.81 per share Applied to 1,347 common shares in code F transaction

Restricted stock units held after transaction 25,054 units Direct RSU holdings following September 10, 2026 exercise

Initial vesting portion 25.0% RSUs vest 25% on the first anniversary of the grant date

Ongoing quarterly vesting rate 6.25% per quarter Remaining RSUs vest 6.25% quarterly until fully vested

Key Terms

Restricted Stock Unit, vesting schedule, Payment of exercise price or tax liability by delivering or withholding securities

3 terms

Restricted Stock Unit financial

"Each restricted stock unit represents the contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

vesting schedule financial

"The restricted stock units have a 4-year vesting schedule"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

Payment of exercise price or tax liability by delivering or withholding securities financial

"Payment of exercise price or tax liability by delivering or withholding securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity transaction did GILD’s CFO report on September 10, 2026?

Gilead Sciences’ CFO Andrew D. Dickinson reported exercising 2,797 restricted stock units, receiving the same number of common shares, and having 1,347 shares delivered or withheld to cover the exercise price or tax liability.

How many GILD restricted stock units did the CFO hold after the reported transaction?

After the September 10, 2026 transaction, the CFO directly held 25,054 restricted stock units, each representing the contingent right to receive one share of Gilead Sciences’ common stock, subject to the vesting schedule described.

What price was used for the GILD shares delivered or withheld for tax or exercise obligations?

For the payment of exercise price or tax liability, 1,347 shares of Gilead Sciences common stock were delivered or withheld at $144.81 per share, as reported for the code F transaction on September 10, 2026.

Were the GILD CFO’s transactions made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported for these transactions, so they are not identified as being executed under a pre-arranged trading plan.

What does each GILD restricted stock unit represent for the CFO?

Each restricted stock unit reported for the Gilead Sciences CFO represents the contingent right to receive one share of Gilead Sciences, Inc.’s common stock, subject to the vesting schedule described in the filing footnotes.

What is the vesting schedule for the GILD restricted stock units involved in this filing?

The restricted stock units have a 4-year vesting schedule: 25% vest on the first anniversary of the grant date, and the remaining units vest 6.25% quarterly thereafter until fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 06:31 PM Accepted by SEC EDGAR 09/11/2026 - 06:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dickinson Andrew D

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		M		2,797	A	(1)	168,443	D
Common Stock	09/10/2026		F		1,347	D	$144.81	167,096	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	09/10/2026		M			2,797	(2)	(2)	Common Stock	2,797	(1)	25,054	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Amy Kim by Power of Attorney for Andrew D. Dickinson	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)